The future of diagnostics in the evolving Alzheimer’s disease care landscape

Alzheimer's disease (AD) affects approximately 6.7 million people, and that number is expected to nearly double by 2050.1 Confirmation of amyloid pathology is recommended in the appropriate-use guidelines for newly approved and emerging disease-modifying therapies (DMTs). Now is the time for healthcare professionals and institutions to prepare to meet the demand for diagnostics to streamline and accelerate the path to the right treatment, at the right time.

The FDA-cleared Elecsys® Alzheimer’s cerebrospinal fluid (CSF) ratios, pTau181/Abeta42 and tTau/Abeta42, confirm amyloid pathology in the brain and support diagnosis at early disease stages, when treatment is most effective. 

Hear from Maria-Magdalena Patru, M.D., Ph.D., scientific partner, and Laura Parnas, Ph.D., disease area network lead, cardiometabolism and neurology, Roche Diagnostics, about the importance of clinical labs in diagnosing early-stage AD.

Download our presentation to gain knowledgeable insights on Alzheimer's disease. 

Form Successfully Submitted!
Thank you for your submission!


  1. Alzheimer’s Association. Accessed July 3, 2023.